Quantitative analysis on the characteristics of targets with FDA approved drugs

International Journal of Biological Sciences

Volumn 4, Issue 1, 2008, Pages 15-22

  Sakharkar, Meena K ^a,b   Li, Peng ^a   Zhong, Zhaowei ^a   Sakharkar, Kishore R ^b  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Disease; Drug; FDA; Homologs; Pfam; Protein protein interactions; Target; Tissue

Indexed keywords

AMINOCAPROIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ARGATROBAN; BETAMETHASONE; BICALUTAMIDE; BUDESONIDE; CONJUGATED ESTROGEN; DOCETAXEL; ENOXAPARIN; ERLOTINIB; ESTRADIOL; ESTRAMUSTINE; ETHINYLESTRADIOL; FLUTAMIDE; FULVESTRANT; GEFITINIB; HEPARIN; HYDROCORTISONE; IMATINIB; MEDROXYPROGESTERONE; METHYLPREDNISOLONE; OXANDROLONE; PACLITAXEL; PHOTOFRIN; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TAZAROTENE; TESTOSTERONE; UNINDEXED DRUG;

ARTICLE; COMPUTER MODEL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG MARKETING; DRUG TARGETING; EXON; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; GENETIC VARIABILITY; GENOMICS; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; HUMAN; LEGAL ASPECT; PHARMACOLOGY; UNITED STATES;

DRUG APPROVAL; HUMANS; PHARMACOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38049162232     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4.15     Document Type: Article

References (28)

1. Loging W, Harland L, Williams-Jones B. High-throughput electronic biology: mining information for drug discovery. Nat Rev Drug Discov. 2007; 6: 220-30.
2. Ofran Y, Punta M, Schneider R, Rost B. Beyond annotation transfer by homology: novel protein-function prediction methods to assist drug discovery. Drug Discov. Today. 2005; 21: 1475-82.
3. Zheng C et al. Progress and problems in the exploration of therapeutic targets. Drug Discov. Today. 2006; 11: 412-20.
4. Lindsay MA. Finding new drug targets in the 21st century. Drug Discov. Today. 2005; 10: 1683-87.
5. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov. Today. 2005; 10: 139-47.
6. Hardy LW, Peet NP. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. Drug Discov. Today. 2004; 9: 117-26.
7. Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Discov. 2002; 1: 727-30.
8. Wang S et al. Tools for target identification and validation. Curr. Opin. Chem. Biol. 2004; 8: 371-77.
9. Kramer R, Cohen D. Functional genomics to new drug targets. Nat. Rev. Drug Discov. 2004; 3: 965-72.
10. Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMRbased screening data. J. Med. Chem. 2005; 48: 2518-25.
11. Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov. Today. 2005; 10: 1675-82.
12. Han LY, Cai CZ, Ji ZL, Cao ZW, Chen YZ. Predicting functional family of novel enzymes irrespective of sequence similarity: a statistical learning approach. Nucleic Acids Res. 2004; 32: 6437-44.
13. Sakharkar MK, Sakharkar KR, Pervaiz S. Druggability of human disease genes. Int J Biochem Cell Biol. 2007; 39:1156-64.
14. Safran M, Solomon I, Shmueli O, Lapidot M, Shen-Orr S, Adato A, et al. GeneCards 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics. 2002; 18: 1542-43.
15. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006; 34: D668-72.
16. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: A General Repository for Interaction Datasets. Nucleic Acids Res. 2006; 34: D535-39.
17. Boeckmann B, Bairoch A, Apweiler R, Blatter M, Estreicher A, Gasteiger E, Martin MJ et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res. 2003; 31: 365-70
18. Finn RD, Mistry J, Schuster-Bockler B, Griffiths-Jones S, Hollich V, Lassmann T, et al. Pfam: clans, web tools and services. Nucleic Acids Res. 2006; 34: D247-51.
19. Caskey TC. The Drug Development Crisis: Efficiency and Safety. Annual Review of Medicine 2007; 58: 1-16.
20. Mulder BJ, van der Doef RM, van der Wall EE, Tijssen JG, Piek JJ, van der Meer J, et al. Effect of various antithrombotic regimens (aspirin, aspirin plus dipyridamole, anticoagulants) on the functional status of patients and grafts one year after coronary artery bypass grafting. Eur Heart J. 1994; 15:1129-34.
21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71.
22. Drews J. Proceedings of the Roche Symposium "The Genetic Basis of Human Disease". In: Drews J, Ryser S, eds. Human Disease - From Genetic Causes to Biochemical Effects. Berlin: Blackwell. 1997: 5-9.
23. Drews J. Strategic choices facing the pharmaceutical industry: a case for innovation. Drug Discov Today. 1997; 2:72-8.
24. Ohlstein EH, Ruffolo RR Jr, and Elliott JD. Drug discovery in the next millennium. Annu Rev Pharmacol Toxicol. 2000; 40:177-91.
25. Terstappen GC and Reggiani A. In silico research in drug discovery. Trends Pharmacol Sci. 2001; 22: 23-6.
26. Sakharkar MK, Kangueane P, Petrov DA, Kolaskar AS, Subbiah S. SEGE: A database on 'intron less/single exonic' genes from eukaryotes. Bioinformatics. 2002; 18: 1266-7.
27. Gentles AJ, Karlin S. Why are human G-protein coupled receptors predominantly intronless? Trends Genet. 1999; 15: 47-9.
28. Levanon EY, Sorek R. The importance of alternative splicing in the drug discovery process. Targets. 2003; 2: 109-14.